Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bone loss, in malignant or non-malignant diseases, is caused by increased osteoclast resorption and/or reduced osteoblast bone formation, and is commonly associated with skeletal complications. Thus, there is a need to identify new agents capable of influencing bone remodeling. We aimed to further pre-clinically evaluate the effects of dasatinib (BMS-354825), a multitargeted tyrosine kinase inhibitor, on osteoblast and osteoclast differentiation and function. METHODS: For studies on osteoblasts, primary human bone marrow mensenchymal stem cells (hMSCs) together with the hMSC-TERT and the MG-63 cell lines were employed. Osteoclasts were generated from peripheral blood mononuclear cells (PBMC) of healthy volunteers. Skeletally-immature CD1 mice were used in the in vivo model. RESULTS: Dasatinib inhibited the platelet derived growth factor receptor-β (PDGFR-β), c-Src and c-Kit phosphorylation in hMSC-TERT and MG-63 cell lines, which was associated with decreased cell proliferation and activation of canonical Wnt signaling. Treatment of MSCs from healthy donors, but also from multiple myeloma patients with low doses of dasatinib (2-5 nM), promoted its osteogenic differentiation and matrix mineralization. The bone anabolic effect of dasatinib was also observed in vivo by targeting endogenous osteoprogenitors, as assessed by elevated serum levels of bone formation markers, and increased trabecular microarchitecture and number of osteoblast-like cells. By in vitro exposure of hemopoietic progenitors to a similar range of dasatinib concentrations (1-2 nM), novel biological sequelae relative to inhibition of osteoclast formation and resorptive function were identified, including F-actin ring disruption, reduced levels of c-Fos and of nuclear factor of activated T cells 1 (NFATc1) in the nucleus, together with lowered cathepsin K, αVβ3 integrin and CCR1 expression. CONCLUSIONS: Low dasatinib concentrations show convergent bone anabolic and reduced bone resorption effects, which suggests its potential use for the treatment of bone diseases such as osteoporosis, osteolytic bone metastasis and myeloma bone disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962 · cited 1×
“The c-Src kinase is an essential molecule for OC resorption, intervening in the aVb3 integrin outside-in signaling in the sealing zone between the OC and the bone matrix [43]; in accordance with these observations, c-Src -/- mice show an osteopetrotic phenotype with OCs unable to form ruffled borders despite a normal…”
ResultOsteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
The role of NFAT in osteoclast formation
TAKAYANAGI, H. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.071 · Cited by 442 · cited 1×
“[45,48] is retained in the cytoplasmic fraction while nuclear”
BackgroundBone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Giuliani, N., Rizzoli, V., & Roodman, G. D. (2006) · Blood · doi:10.1182/blood-2006-05-026112 · Cited by 302
Luo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1112 · Cited by 151
Self-citationGarayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148
Self-citation
Cited by
Ségaliny, A. I., Tellez-Gabriel, M., Heymann, M.-F., & Heymann, D. (2015) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.01.001 · Cited by 164
Age-associated callus senescent cells produce TGF-β1 that inhibits fracture healing in aged mice
Liu, J., Zhang, J., Lin, X., Boyce, B. F., Zhang, H., & Xing, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148073 · Cited by 112
“Dasatinib affects bone remodeling via the regulation of both OBs and OCs (49, 50).”
BackgroundGarcia-Gomez, A., Li, T., de la Calle-Fabregat, C., Rodríguez-Ubreva, J., Ciudad, L., Català-Moll, F., Godoy-Tena, G., Martín-Sánchez, M., San-Segundo, L., Muntión, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20715-x · Cited by 57
Self-citationBreccia, M., Molica, M., & Alimena, G. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.09.016 · Cited by 54
Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair
Wang, M., Park, S., Nam, Y., Nielsen, J., Low, S. A., Srinivasarao, M., & Low, P. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00660 · Cited by 24
Metadata
- Authors
- Garcia-Gomez, A., Ocio, E. M., Crusoe, E., Santamaria, C., Hernández-Campo, P., Blanco, J. F., Sanchez-Guijo, F. M., Hernández-Iglesias, T., Briñón, J. G., Fisac-Herrero, R. M., Lee, F. Y., Pandiella, A., San Miguel, J. F., & Garayoa, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-23
- Volume
- 7
- Issue
- 4
- Pages
- e34914
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1988622995
- Cited by
- 76
- References
- 8
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. https://app.cochat.ai/papers/10.1371/journal.pone.0034914
- The paper
- Garcia-Gomez, A., Ocio, E. M., Crusoe, E., Santamaria, C., Hernández-Campo, P., Blanco, J. F., Sanchez-Guijo, F. M., Hernández-Iglesias, T., Briñón, J. G., Fisac-Herrero, R. M., Lee, F. Y., Pandiella, A., San Miguel, J. F., & Garayoa, M. (2012). Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. PLoS ONE. https://doi.org/10.1371/journal.pone.0034914
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.